UNSPSC 51241129: Carboxymethylcellulose sodium

This classification denotes a non-current chemotherapy regimen or association, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K679OBS311. European Medicines Agency schedules Carboxymethylcellulose sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01063MIG. Carboxymethylcellulose sodium generally arises in the molecular formula (C6H7O5(H)MOD(C2H2O2)MOD(NA)MOD)N. The term 'carboxymethylcellulose sodium' is a European Pharmacopoeia designation.

As of Q4 2014, CARBOXYMETHYLCELLULOSE SODIUM remains the US FDA Preferred Term for this commodity. Carboxymethylcellulose sodium bears US NLM identifiers UMLS ID C0037487 and NCI Concept Code C83596. SMILES: [NA].OC(C(O)C(O)C=O)C(O)CO.OC(=O)C.

UNSPSC 51241129 Carboxymethylcellulose sodium is a Commodity code covering chemical compounds used in pharmaceutical formulations and over-the-counter products. State and local governments procure this material primarily as a component within multi-source generic pharmaceutical and OTC product supply chains rather than as a standalone input. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity under this code. MMCAP coordinates procurement across participating state and local government facilities in Minnesota and Oregon, leveraging cooperative purchasing vehicles to establish master agreements with multiple pharmaceutical manufacturers and suppliers. The scope of work involves securing comprehensive pharmaceutical product supply with specific formulations, National Drug Codes (NDCs), and packaging configurations, with carboxymethylcellulose sodium appearing as a component within broader generic medication offerings rather than as a line-item commodity on its own.

The geographic spread is concentrated in Minnesota and Oregon, with activity driven through MMCAP's multistate cooperative mechanism. The representative recent opportunity is MMCAP's Request for Proposal S1070000015802, posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products. The RFP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), demonstrate current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three wholesalers with chargeback systems, and offer flexible pricing structures (flat price, net price formats, or WAC-minus). Products must be available by May 15, 2026, with resulting contracts effective July 1, 2026. The contract term is two years for new vendors with optional extensions, and evaluation is weighted heavily toward price competitiveness (75 percent) with secondary weight on fixed pricing (10 percent) and compliance with data format and EDI requirements (5 percent each).